Daily injection could free kids from IV nutrition dependency
NCT ID NCT03562130
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This study tested a daily injection called teduglutide (Revestive) in 25 children aged 2 to 18 with short bowel syndrome who rely on IV nutrition. The goal was to see if the drug helps their intestines absorb more nutrients, so they can reduce or stop IV feedings. Researchers measured changes in IV nutrition needs, stool output, and quality of life over the long term.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Teduglutide (Revestive), a daily injection that helps the intestines absorb more nutrients
- What this could lead to
- If it works, this could help children with short bowel syndrome reduce or stop needing IV nutrition, improving their daily life and reducing complications.
- What could go wrong
- This is a small, single-center study with only 25 children, so results may not apply to everyone. The treatment requires daily injections and may not work for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SHORT BOWEL SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Necker - Enfants malades
Paris, 75015, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Measuring hidden energy needs: a clue to better nutrition for gut failure patients
- Weekly shot could help people with short bowel syndrome absorb more fluids
- New drug could cut IV nutrition needs for short bowel patients
- Could a Plant-Based powder cut the need for IV nutrition?
- Growth hormone shows promise for weaning kids off IV nutrition
- New drug teduglutide monitored in 250 patients with short bowel syndrome